Synthaverse S.A.
Develops and sells oncology, hematology, and immunology drugs and vaccines globally.
BML | WAR
Overview
Corporate Details
- ISIN(s):
- PLBMDLB00018 (+3 more)
- LEI:
- 259400OWZM67D079S374
- Country:
- Poland
- Address:
- LUBLIN UNIWERSYTECKA 10, 20-029 LUBLIN
- Website:
- https://synthaverse.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Synthaverse S.A. is a pharmaceutical and biotechnology company with a history dating back to 1944. The company develops, manufactures, and sells medicinal products (both prescription and OTC), medical devices, and laboratory reagents. Its portfolio focuses on treatments in the areas of oncology, hematology, and immunology, with products sold in approximately 50 countries. Key brands include Onko BCG, a drug for bladder cancer, and the BCG 10 anti-tuberculosis vaccine, for which the company is the sole supplier in Poland. Synthaverse emphasizes the use of its own proprietary technologies and close cooperation with scientific centers to drive research and innovation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-30 22:10 |
Audit Report / Information
zal03_Synthaverse_30.06.2025_Raport_z_przegladu_srodrocznego_skroconego_JSF_MSS…
|
Polish | 398.4 KB | ||
| 2025-09-30 22:10 |
Management Discussion and Analysis
zal02_sprawozdanie_zarzadu_z_dzialalnosci_spolki_za_I_polrocze_2025.pdf
|
Polish | 1.5 MB | ||
| 2025-09-30 22:10 |
Interim Report
zal01_skrocone_srodroczne_sprawozdanie_finansowe_za_okres_od_01_01_2025_do_30_0…
|
Polish | 2.7 MB | ||
| 2025-09-29 08:35 |
Regulatory News Service
Zawarcie istotnej umowy handlowej - Content (PL)
|
Polish | 5.2 KB | ||
| 2025-09-17 14:03 |
Legal Proceedings Report
Informacja o wniesieniu powództwa o uchylenie lub stwierdzenie nieważności uchw…
|
Polish | 4.1 KB | ||
| 2025-09-08 08:48 |
Regulatory News Service
Zatwierdzenie przez Prezesa URPL zwiększenia wielkości serii Onko BCG 100 - Con…
|
Polish | 1.6 KB | ||
| 2025-08-27 15:08 |
Share Issue/Capital Change
Zawarcie umowy objęcia akcji serii W - Content (PL)
|
Polish | 1.9 KB | ||
| 2025-08-26 19:40 |
Share Issue/Capital Change
zal01_uchwala_Zarzadu_nr_6_2025.pdf
|
Polish | 407.8 KB | ||
| 2025-08-26 19:40 |
Share Issue/Capital Change
Podwyższenie kapitału zakładowego w ramach kapitału docelowego poprzez emisję a…
|
Polish | 2.5 KB | ||
| 2025-08-25 12:37 |
Registration Form
zal01_STATUT_tekst_jedn._na_31.07.2025.pdf
|
Polish | 663.4 KB | ||
| 2025-08-25 12:37 |
Registration Form
Rejestracja przez sąd zmiany statutu emitenta - Content (PL)
|
Polish | 5.2 KB | ||
| 2025-08-01 11:16 |
Declaration of Voting Results & Voting Rights Announcements
zal01_ESPI-wykaz-akcjonariuszy-posiadajacych-co-najmniej-5-glosow-na-NWZA-31.07…
|
Polish | 142.0 KB | ||
| 2025-08-01 11:16 |
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym…
|
Polish | 351 bytes | ||
| 2025-08-01 11:10 |
Post-Annual General Meeting Information
zal01_UCHWALY_PODJETE_NWZA_31.07.2025.pdf
|
Polish | 247.2 KB | ||
| 2025-08-01 11:10 |
Declaration of Voting Results & Voting Rights Announcements
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Emitenta w dniu 31…
|
Polish | 1.1 KB |
Automate Your Workflow. Get a real-time feed of all Synthaverse S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Synthaverse S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
